Premier Laboratory Partner for a Better World
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us.
Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, Agilent provides laboratory solutions to meet their full spectrum of needs. We work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. Our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.
Customers trust Agilent for solutions that enable insights...for a better world.
Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound’s biological mechanism of action.
Arpeggio's Clarion Technology provides valuable insight into a compound's mechanism of action by identifying the direct transcriptional targets of a drug in fifteen minutes or less while also capturing a snapshot of cell state at any given time. By combining nascent sequencing with proprietary algorithms, we identify not only direct gene targets, but also transcription factor and enhancer RNA activity not attainable by any other technologies.
Joey Azofeifa, PhD – Founder, President, and Chief Science Officer
Daniel Weaver, PhD – Founder and Chief Executive Officer
Edgewise Therapeutics was founded in July 2017 and solely funded by a venture healthcare firm, OrbiMed Advisors. Our mission is to discover and develop new small molecule therapies for important musculo-skeletal disorders. Edgewise currently has 9 full time employees working in scientific operations, chemistry, biophysics, and physiology. The company is largely virtual with internal physiology expertise augmented by CU collaborations and contract research organizations in Europe, the US and China. We are also in collaboration with Leslie Leinwand’s lab (BioFrontiers) regarding protein production and compound characterization, and Roger Enoka (CU Integrative Physiology) to understand effects of compounds on integrative physical function. The Edgewise team is led by our CEO, Kevin Koch, who co-founded Array Biopharma and is Venture Partner with OrbiMed Advisors, and our CSO Alan Russell, who is Ex-VP and Head of the Muscle Research Group at GSK in Pennsylvania, as well as an Adjunct Professor with CU Integrative Physiology.
Laura Hunter LHunter@edgewisetx.com
Alan Russel email@example.com
Kevin Koch firstname.lastname@example.org
See Like No Other
Double Helix is a team of top talent from a range of fields coming together to advance discovery and research in precision 3D nano-imaging. We have recognized world experts in super-resolution, first-rate engineers in optics, 3D imaging, software,and advisors from the research and business world. We are experts in our fields, collaborators in others, and excited by discovery.
Mosaic Biosciences is advancing a fundamentally new class of synthetic materials to support native tissue regeneration. Mosaic’s versatile technology platform provides the leading biomaterial for cell and drug delivery, regenerative medicine, and tissue sealants.
Mosaic products are based on its patented thiol-ene click chemistry and proprietary modular polymer platform. These technologies provide Mosaic with the unprecedented flexibility to create a range of novel biomaterials that are ideally suited to applications ranging from nano-particles to drug delivery matrices to scaffolds for tissue repair and regeneration.
Vaccines provide perhaps the single most cost-effective disease prevention modality currently available. Several significant issues persist, however, with respect to the availability and uptake of vaccines, particularly in resource-limited regions of the world. These include cost, stability within a cold-chain supply, delivery, adjuvants, acceptance, and compliance. The scientific founders of VitriVax have developed two technologies that–when combined–address these challenges.
Michael Artinger, PhD – CEO
Robert Garcea, MD – Co-founder and CSO
Theodore Randolph, PhD – Co-founder and CTO
Headquartered out of Nobel Laureate Tom Cech's Biofrontiers Institute at the University of Colorado, WAVi Research has created and analyzed data sets that include pre-symptom Alzheimer's; a 6-year longitudinal concussion study on NCAA athletes; studies on hearing loss and mental function; correlations between heart and brain health; and the effects of interventions on brain performance, including the effects of ADHD medication. Recently, WAVi has been awarded an NIH grant to study acute pain and opioid abuse. WAVi also helps promote its clinicians through open research collaborations made available by the WAVi cloud application.